A different kind of "drug war" will play out this month in the U.S. Supreme Court in a potentially landmark patent challenge with huge implications for biomedical and biotechnology industries' role in the development of new drugs. The case, Merck KGAA v. Integra LifeSciences, asks how far down the chain of research and experimentation a federal safe harbor statute reaches to protect drug manufacturers from liability for patent infringement.
Details here from The National Law Journal via Law.com.